The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()

KP1339 is a promising ruthenium-based anticancer compound in early clinical development. This study aimed to test the effects of KP1339 on the in vitro and in vivo activity of the multi-kinase inhibitor sorafenib, the current standard first-line therapy for advanced hepatoma. Anticancer activity of...

Descripción completa

Detalles Bibliográficos
Autores principales: Heffeter, Petra, Atil, Bihter, Kryeziu, Kushtrim, Groza, Diana, Koellensperger, Gunda, Körner, Wilfried, Jungwirth, Ute, Mohr, Thomas, Keppler, Bernhard K., Berger, Walter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807657/
https://www.ncbi.nlm.nih.gov/pubmed/23790465
http://dx.doi.org/10.1016/j.ejca.2013.05.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3807657/
https://www.ncbi.nlm.nih.gov/pubmed/23790465
http://dx.doi.org/10.1016/j.ejca.2013.05.018

Ejemplares similares